Enlivex Therapeutics Ltd.
Nasdaq ENLV · Tel Aviv, Israel
Works in Dermatology · GI & liver · Infectious disease · Musculoskeletal · Renal & urogenital · Respiratory · Women's health
Enlivex Therapeutics Ltd. is a clinical trial sponsor based in Tel Aviv, Israel, listed as Nasdaq ENLV. It has 2 active clinical trials with 342 planned participants, across 7 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq ENLV
Fundraising
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 342 planned participants, in Dermatology, GI & liver, Infectious disease, Musculoskeletal and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
Enlivex Therapeutics Ltd is based in Tel Aviv, Israel and is listed as Nasdaq ENLV. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Enlivex Therapeutics Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Approve Suite is not affiliated with Enlivex Therapeutics Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.